# Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults

> **NCT06028347** · PHASE1 · COMPLETED · sponsor: **Seqirus** · enrollment: 96 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** sa-mRNA vaccine Dose 1
- **BIOLOGICAL:** sa-mRNA vaccine Dose 2
- **BIOLOGICAL:** sa-mRNA vaccine Dose 3
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06028347
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-05
- **Primary completion:** 2024-10-13
- **Final completion:** 2024-10-13
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06028347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06028347, "Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06028347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*